Idera Pharmaceuticals, Inc.

Hybridon, Inc.

Idera Pharmaceutials, Inc.

Ekambar R Kandimalla

Sudhir Agrawal

Dong Yu

Lakshmi Bhagat

Daqing Wang

Mallikarjuna Putta

Yukui Li

Tao Lan

Qiuyan Zhao

Ireneusz Nowak

FuGang Zhu

Fu-Gang Zhu

Rajendra K Pandey

Bhagat Lakshmi

Ivan Habus

Nicola LaMonica

Victoria Jane Philbin

Weiwen Jiang

Michael Reardon

Millikarjuna Putta

Wang Daqing

Zhu Fugang

Agrawal Sudhir

Quiyan Zhao

Mallikarjuna Reddy Putta

The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.

Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8

The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs and potentiators of anti-inflammatory agents that inhibit TNF for the prevention and treatment of inflammatory and autoimmune diseases.

Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9

The invention provides immunostimulatory oligonucleotides having at least one CpG dinucleotide and a secondary structure at the 5'- or 3&#x2032;-end. These oligonucleotides have either reduced or improved immunostimulatory properties. The invention establishes that 5&#x2032;-terminal secondary structures affect immunostimulatory activity significantly more than those at the 3&#x2032;-end. The invention also provides methods for increasing or decreasing the immunostimulatory activity of a CpG-containing nucleic acid.

Stabilized immunomodulatory oligonucleotides

The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3' ends and a linker at the 5&#x2032; ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.

Compositions for inhibiting gene expression and uses thereof

The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR ligand or TLR signaling agonist. The methods may have use in the prevention and treatment of autoimmunity, inflammation, inflammatory bowel disease, lupus, allergy, asthma, infection, sepsis, cancer and immunodeficiency.

Toll like receptor modulators

The invention provides the use of TLR inhibitors or a pharmaceutically acceptable derivative thereof, optionally in combination with one or more lipid lowering composition, cholesterol lowering composition, diuretics, non-steroidal anti-inflammatory compounds (NSAIDs), antibodies, antisense oligonucleotides, TLR agonists, TLR antagonists, peptides, proteins or gene therapy vectors or combinations thereof for the prevention or treatment of hypercholesterolemia and/or hyperlipidemia and/or diseases associated therewith.

Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto

The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.

Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes

Growing community of inventors

Southboro, MA, United States of America

Ekambar R Kandimalla